SCHEMBL3407396

SCHEMBL3407396

CCC(=O)c1cc(OC)c(OC)c(OC)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.65
KMT2A Q03164 4/20 0.65
ALDH1A1 P00352 3/20 0.65
KDM4E B2RXH2 2/20 0.65
GAA P10253 1/20 0.59
MAPK1 P28482 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.53
TUBB4A P04350 1/20 0.51
TUBB P07437 1/20 0.51
TUBA3C P0DPH7 1/20 0.51
TUBA1B P68363 1/20 0.51
TUBA4A P68366 1/20 0.51
TUBB4B P68371 1/20 0.51
TUBB3 Q13509 1/20 0.51
TUBB2A Q13885 1/20 0.51
TUBB8 Q3ZCM7 1/20 0.51
TUBA3E Q6PEY2 1/20 0.51
TUBA1A Q71U36 1/20 0.51
TUBA1C Q9BQE3 1/20 0.51
TUBB6 Q9BUF5 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dimethylamine SCHEMBL7122394 0.94 ALDH1A1 (0.64) MEN1KMT2AALDH1A1KDM4EGAA
SCHEMBL8430195 0.91 ALDH1A1 (0.60) MEN1KMT2AALDH1A1KDM4EGAA
SCHEMBL27823832 0.88 ALDH1A1 (0.62) MEN1KMT2AALDH1A1KDM4EGAA
SCHEMBL8430188 0.88 TSHR (0.66) MEN1KMT2AALDH1A1KDM4EGAA
SCHEMBL8430187 0.87 BPTF (0.56) MEN1KMT2AALDH1A1KDM4EGAA
SCHEMBL9828028 0.86 MEN1 (0.62) MEN1KMT2AALDH1A1KDM4EGAA
SCHEMBL7046987 0.86 ALDH1A1 (0.72) MEN1KMT2AALDH1A1KDM4EGAA
SCHEMBL7837299 0.85 ALDH1A1 (0.61) MEN1KMT2AALDH1A1KDM4EGAA
SCHEMBL25238149 0.84 ALDH1A1 (0.60) MEN1KMT2AALDH1A1KDM4EGAA
SCHEMBL9702085 0.84 PKM (0.62) MEN1KMT2AALDH1A1KDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3661902-B1 METHOD FOR THE DEACYLATION AND/OR DEALKYLATION OF COMPOUNDS UNIV ANTWERPEN (BE) 2025-07-16 EP claimed
US-20210130273-A1 METHOD FOR THE DEACYLATION AND/OR DEALKYLATION OF COMPOUNDS UNIVERSITEIT ANTWERPEN (BE) 2021-05-06 US claimed
CN-111542509-A Method for deacylation and/or dealkylation of compounds 安特卫普大学 2020-08-14 CN claimed
EP-3661902-A1 METHOD FOR THE DEACYLATION AND/OR DEALKYLATION OF COMPOUNDS Universiteit Antwerpen (BE) 2020-06-10 EP claimed
WO-2019025535-A1 METHOD FOR THE DEACYLATION AND/OR DEALKYLATION OF COMPOUNDS UNIVERSITEIT ANTWERPEN (BE) 2019-02-07 WO claimed
EP-3661902-B1 METHOD FOR THE DEACYLATION AND/OR DEALKYLATION OF COMPOUNDS UNIV ANTWERPEN (BE) 2025-07-16 EP disclosed
CN-110526854-B Alpha, beta-unsaturated ketone derivative, preparation method and application thereof as medicine 宁夏医科大学 2023-12-15 CN disclosed
EP-3904330-A1 ETHYLENEDIAMINE COMPOUND AND USE THEREOF Academy Of Military Medical Sciences (CN) 2021-11-03 EP disclosed
US-20210130273-A1 METHOD FOR THE DEACYLATION AND/OR DEALKYLATION OF COMPOUNDS UNIVERSITEIT ANTWERPEN (BE) 2021-05-06 US disclosed
WO-2021017795-A1 α,β-UNSATURATED KETONE DERIVATIVE, PREPARATION METHOD AND USE AS MEDICINE 宁夏医科大学 2021-02-04 WO disclosed
WO-2021017795-A1 α,β-UNSATURATED KETONE DERIVATIVE, PREPARATION METHOD AND USE AS MEDICINE 宁夏医科大学 2021-02-04 WO disclosed
CN-108299458-B Oridonin derivative and preparation method and application thereof 青岛海洋生物医药研究院股份有限公司 2020-10-02 CN disclosed
EP-0680950-B1 PROPENONE DERIVATIVES KYOWA HAKKO KOGYO KK (JP) 2001-05-23 EP disclosed
US-5952355-A 1-ETHER-SUBSTITUTED PHENYL-3-INDOL-3-YL-2-PROPEN-1-ONE DERIVATIVES; ANTITUMOR AND -CARCINOGENIC AGENTS; IMMUNOSUPPRESSANTS; AUTOIMMUNE DISEASES; SIDE EFFECT REDUCTION KYOWA HAKKO KOGYO CO., LTD. (JP) 1999-09-14 US disclosed
EP-0812825-A1 PROPENONE DERIVATIVES KYOWA HAKKO KOGYO CO., LTD. (JP) 1997-12-17 EP disclosed
EP-0680950-A1 PROPENONE DERIVATIVE KYOWA HAKKO KOGYO CO., LTD. (JP) 1995-11-08 EP disclosed
EP-0322033-A2 New 2,5-diaryl tetrahydrofurans and analogs thereof as paf antagonists MERCK & CO. INC. (US) 1989-06-28 EP disclosed
US-4757084-A Pharmaceuticals MERCK & CO., INC. (US) 1988-07-12 US disclosed
EP-0217204-A1 Trans-2-(3,4,5-trimethoxyphenyl)-5-(5,6-dimethoxy-3-pyridyl)-tetrahydrothiophene, a PAF-antagonist MERCK & CO. INC. (US) 1987-04-08 EP disclosed
EP-0154887-A1 New 2,5-diaryl tetrahydrothiophenes and analogs thereof as paf-antagonists MERCK & CO. INC. (US) 1985-09-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210130273-A1 METHOD FOR THE DEACYLATION AND/OR DEALKYLATION OF COMPOUNDS HAAO, TDO2, HPD MEN1 3750/4885KMT2A 1208/4885ALDH1A1 708/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.